Latest news with #AstraZenecaPlc
Yahoo
3 days ago
- Business
- Yahoo
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6. In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP). Topline data were shared in indicated that the Enhertu combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups. Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP. The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination. The MATTERHORN trial assessed Imfinzi (durvalumab) with standard FLOT chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone. Topline data were released in March. A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death. Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone. A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow. The SERENA-6 trial investigated camizestrant combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor. Topline data were shared in February. The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%. Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm. While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2. Price Action: AZN stock is trading lower by 0.95% at $72.14 at last checkMonday. Read Next:Photo by Piotr Swat Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Economic Times
4 days ago
- Business
- Economic Times
AstraZeneca breast cancer medicine slows disease by over six months
Agencies Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow. New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant, in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment. Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients. Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow. When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
Time of India
4 days ago
- Business
- Time of India
AstraZeneca breast cancer medicine slows disease by over six months
AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in trials. Camizestrant, combined with other medicines, helped patients live longer without cancer worsening. AstraZeneca hopes this data will establish a new treatment approach. The company anticipates significant sales, though analysts offer more conservative estimates. Tired of too many ads? Remove Ads New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant , in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
Yahoo
02-05-2025
- Business
- Yahoo
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and Symbicort pressurized metered-dose inhaler (pMDI). KALOS and LOGOS included approximately 4,400 randomized trials met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. No new safety or tolerability signals were identified for Breztri in KALOS or LOGOS. Full results from the two Phase 3 trials will be shared with regulatory authorities and presented at an upcoming medical meeting. Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan. In addition to the two registrational trials (KALOS and LOGOS), two qualifying trials, LITHOS and VATHOS, also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients. In April, Sanofi SA (NASDAQ:SNY) reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in heterogeneous inflammatory asthma. The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses. Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60. A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident. In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60. AstraZeneca announced in its first-quarter presentation (PDF) on Tuesday that it had stopped working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain and painful diabetic neuropathy. On Tuesday, the European pharma giant reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion, driven by double-digit growth in oncology and biopharmaceuticals. Price Action: AZN stock is up 1.52% at $71.58 at the last check Friday. Read Next:Photo by Piotr Swat Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Mint
29-04-2025
- Business
- Mint
AstraZeneca's Soriot Warns US Against Trade Tariffs on Medicines
AstraZeneca Plc's Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on medicines. 'We actually believe that a better incentive to attract investment in manufacturing and in R&D is to have a great tax policy that incentivizes companies to invest in the country,' Soriot said on Bloomberg TV on Tuesday. AstraZeneca believes any impact of levies on the company would be short-lived given its manufacturing presence in the US. Still, Soriot said the industry is calling on the Trump administration not to put levies on imported medicines, after they were excluded from recent announcements. The drugmaker posted higher profit in the first quarter that still disappointed investors due to weaker than expected sales of key cancer medicines. The company's shares fell as much as 4.7% in early trading in London, and are down about 16% over the past year. Astra said it is discontinuing a late-stage trial of its Truqap prostate cancer treatment, based on a recommendation from an independent data monitoring committee. Truqap is already approved for treating breast cancer. Earnings per share, excluding some items, were $2.49, the company said Tuesday, above the $2.26 estimated by analysts surveyed by Bloomberg. Sales of major cancer medicines were lower than anticipated, with Bloomberg Intelligence analyst John Murphy saying in a note that weakness in cancer and rare disease drugs were a potential source of concern. Still, sales of its diabetes and heart disease drug Farxiga were nearly 6% higher than expected, while revenue from its newer cancer medicine Enhertu was also ahead. The British drugmaker confirmed its guidance for the year and also said it was committed to investing and growing in the US. Astra has already announced a $3.5 billion investment in its US business by the end of 2026. The cash will go toward research and development as well as manufacturing. Astra is also trying to move on from a damaging probe into current and former employees in China that ensnared the drugmaker's president in the country. The company said it received an appraisal opinion in April from Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6 million, which Astra said likely relates to Enhertu. 'A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable,' the company said. Analysts had previously been reassured by Astra's earlier estimate that it could be fined just $4.5 million for suspected unpaid import taxes for two other cancer medicines Imfinzi and Imjudo. The latest update on China would likely be welcomed by investors, Jefferies' analyst Benjamin Jackson said in a note. This year Astra announced a $2.5 billion research hub in Beijing as it seeks to capitalize on booming interest in the scientific prowess emerging in China. The project indicated a strong partnership with the government despite the probe. The drugmaker has had several positive readouts this year from potential blockbuster medicines, including data from its experimental cholesterol drug that significantly reduced 'bad' cholesterol in a mid-stage trial. That could be part of a powerful combination drug targeting weight loss and related ailments. This article was generated from an automated news agency feed without modifications to text. First Published: 29 Apr 2025, 01:36 PM IST
